LeMaitre Vascular
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Operating worldwide, LeMaitre Vascular, Inc. specializes in the development, distribution, and maintenance of medical devices and implants for treating peripheral vascular disease. Its product portfol...
Latest News
10 days ago · seekingalpha.com
LeMaitre Vascular, Inc. (LMAT) Q3 2026 Earnings Call TranscriptLeMaitre Vascular, Inc. ( LMAT ) Q3 2026 Earnings Call November 4, 2026 5:00 PM EST Company Participants Dorian LeBlanc - Chief Financial Officer George LeMaitre - Chairman & CEO Conference Call Participants Michael Petusky - Barrington Research Associates, Inc., Research Division Nathan Treybeck - Wells Fargo Securities, LLC, Research Division Brett Fishbin - KeyBanc Capital Markets Inc., Research Division Daniel Stauder - Citizens JMP Securities, LLC, Research Division James Sidoti - Sidoti & Company, LLC Michael Sarcone - Jefferies LLC, Research Division Presentation Operator Welcome to the LeMaitre Vascular Q3 2026 financial results conference call. As a reminder, today's call is being recorded.
10 days ago · globenewswire.com
LeMaitre to Participate in Upcoming Investor ConferencesBURLINGTON, Mass., Nov. 06, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that management will participate in three upcoming investor conferences.
12 days ago · marketbeat.com
LeMaitre Vascular Q3 Earnings Call HighlightsLeMaitre Vascular NASDAQ: LMAT reported 12% organic sales growth in the third quarter of 2026, driven by higher prices and unit volumes, while reiterating its full-year organic growth outlook and lowering its gross margin forecast.
12 days ago · zacks.com
LeMaitre Vascular (LMAT) Misses Q3 Earnings EstimatesLeMaitre Vascular (LMAT) came out with quarterly earnings of $0.65 per share, missing the Zacks Consensus Estimate of $0.69 per share. This compares to earnings of $0.62 per share a year ago.
1 month ago · globenewswire.com
LeMaitre Will Announce Third Quarter 2026 Earnings Results on November 4, 2026BURLINGTON, Mass., Oct. 12, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will release its third quarter 2026 financial results on Wednesday, November 4, 2026, after the market close. The company has scheduled a conference call for 5:00 PM EST the same day to discuss the results, business highlights, and company outlook.
2 months ago · seekingalpha.com
LeMaitre Vascular: The Q2 Miss Hides A Stronger Acquisition MachineLeMaitre Vascular is rated a "Strong Buy" due to its robust M&A-driven business model, high margins, and recent valuation compression. LMAT's strategic shift to larger, higher-multiple acquisitions has improved its success rate to 80% and driven margin expansion, with gross margin rising from 65% to 72%. The company's healthy balance sheet, $376M in cash/short-term investments, and experienced management underpin its ability to pursue disciplined, accretive deals.
3 months ago · globenewswire.com
LeMaitre to Participate at Upcoming Investor Conferences in SeptemberBURLINGTON, Mass., Aug. 27, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that management will participate in three upcoming investor conferences.
3 months ago · seekingalpha.com
LeMaitre Vascular: 31% Drawdown On $0.02 Guidance CutLeMaitre Vascular remains a Buy after a 31% pullback, though I have trimmed my price target to $95-$100 for year-end 2027. The Q2 2026 miss was tied to currency, export blockages, and tissue shortages. Not underlying demand. Organic sales grew 10%, and margins hit record highs. Artegraft, now 21% of sales, is LMAT's largest and fastest-growing product. It is the main factor behind margin expansion and international growth prospects.
3 months ago · globenewswire.com
LeMaitre to Participate in the 11th Annual Needham Virtual MedTech & Diagnostics 1x1 ConferenceBURLINGTON, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that management will hold investor meetings at the 11th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference on Tuesday, August 11, 2026.
3 months ago · seekingalpha.com
LeMaitre Vascular, Inc. (LMAT) Q2 2026 Earnings Call TranscriptLeMaitre Vascular, Inc. (LMAT) Q2 2026 Earnings Call Transcript
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove LMAT